MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
BeiGene, Ltd. Retained Earnings 2011-2026 | BGNE
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.32 B | -8.61 B | -7.96 B | -7.08 B | -5.08 B | -3.55 B | -1.96 B | -1.01 B | -331 M | -237 M | -118 M | -61.1 M | -42.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -42.8 M | -8.61 B | -3.41 B |
Quarterly Retained Earnings BeiGene, Ltd.
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.09 B | -8.39 B | -8.51 B | -8.61 B | -8.61 B | -8.45 B | -8.33 B | -8.21 B | -7.96 B | -7.59 B | -7.81 B | -7.43 B | -7.08 B | -6.64 B | -5.97 B | -5.4 B | -5.08 B | -4.38 B | -3.97 B | -3.49 B | -3.55 B | -3.55 B | -3.55 B | -3.55 B | -1.96 B | -1.96 B | -1.96 B | -1.96 B | -1.01 B | -1.01 B | -1.01 B | -1.01 B | -331 M | -331 M | -331 M | -331 M | -237 M | -237 M | -237 M | -237 M | -118 M | -118 M | -118 M | -118 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -118 M | -8.61 B | -3.84 B |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-198 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 19.14 | 0.74 % | $ 895 M |  USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 14.74 | -0.2 % | $ 216 M | USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.63 | 3.5 % | $ 434 M |  Britain |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
BioNTech SE
BNTX
|
18 B | $ 94.9 | 0.82 % | $ 22.9 B | Germany |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-512 M | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
-1.62 B | $ 3.13 | -0.48 % | $ 651 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-325 M | - | 0.74 % | $ 768 M |  Israel |
 |
Exelixis
EXEL
|
-76.8 M | $ 49.35 | 2.47 % | $ 13.4 B | USA |
 |
Fortress Biotech
FBIO
|
-734 M | $ 2.36 | -1.26 % | $ 65.8 M | USA |
 |
Forte Biosciences
FBRX
|
-223 M | $ 24.9 | 3.65 % | $ 322 M | USA |
 |
AbbVie
ABBV
|
-15.5 B | $ 203.32 | 0.97 % | $ 360 B | USA |
 |
Gilead Sciences
GILD
|
13.7 B | $ 133.2 | 1.42 % | $ 166 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Compugen Ltd.
CGEN
|
-453 M | $ 2.82 | -2.76 % | $ 263 M | Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
-201 M | - | - | $ 231 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.11 B | $ 0.77 | 0.16 % | $ 35.2 M | Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
-2.2 B | $ 22.41 | 0.04 % | $ 3.71 B | USA |
 |
Genprex
GNPX
|
-171 M | $ 0.85 | -1.99 % | $ 793 K | USA |
 |
Genmab A/S
GMAB
|
7.11 B | $ 26.36 | -0.26 % | $ 1.71 B |  Danmark |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 3.46 | -1.98 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-20.5 M | - | 5.93 % | $ 314 M | Canada |
 |
Grifols, S.A.
GRFS
|
619 M | $ 8.05 | -0.62 % | $ 5.47 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 21.09 | -0.4 % | $ 2.68 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |